Guggenheim Maintains Ionis Pharmaceuticals Buy Rating, Adjusts Price Target
Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Ionis Pharmaceuticals while lowering the price target from $80 to $65.
Stocks · News reference
Analysts upgraded Ionis, CME Group, DigitalOcean, Prologis and Zions Bancorporation, issuing new or revised price targets.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Ionis Pharmaceuticals while lowering the price target from $80 to $65.
The article compares CME Group and Upstart as investment options for 2027. CME Group is a mature, profitable derivatives marketplace with $4 billion in net income, low leverage, and strong free cash flow of $4.2 billion, trading at a lower forward P/E of 25.8. Upstart is a high-growth AI-powered lending platform with 64% revenue growth but carries higher leverage (debt-to-equity of 2.3), negative free cash flow of $166.1 million, and a higher forward P/E of 48.6. The author recommends CME Group for investors seeking stability and dividends, while Upstart appeals to growth-focused investors.
Fed Chair Kevin Warsh's hardline stance on inflation could lead to at least 100 basis points of interest rate hikes by mid-September 2027, according to CME FedWatch forecasts. Rising rates driven by Trump's tariffs, energy disruptions, and AI infrastructure costs could slow the AI data center build-out and trigger valuation re-ratings in an already historically expensive stock market.
Ionis Pharmaceuticals and its partner Biogen reported new two-year data from the Phase 2 CELIA study showing clinical benefit for diranersen in early Alzheimer's disease.
Canadian tenant screening provider FrontLobby has added Equifax credit reports to its service offerings for landlords.
Retail futures broker MetroTrade has launched a rebuilt trading platform and brokerage service in partnership with Payward Services Derivatives, providing expanded access to CME Group futures products.